In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...
Medical science has long been on the hunt for a deeper understanding of the devastating scarring of the body's organs known ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
We quantified the proportion of diagnoses of pulmonary fibrosis (PF) among 25 136 people with lung cancer and 250 583 matched ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback